Canaccord raised the firm’s price target on Stoke Therapeutics (STOK) to $28 from $24 and keeps a Buy rating on the shares. The firm said they raised their target on a higher price estimate and 55% probability of approval for zorevunersen in Dravet syndrome with a potential launch in 2028E.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Positive Outlook for Stoke Therapeutics: Buy Rating Reinforced by Phase 3 Trial Progress and Regulatory Engagement
- Buy Rating for Stoke Therapeutics: Promising Potential of Zorevunersen in Dravet Syndrome Treatment
- Stoke Therapeutics: Promising Outlook with Breakthrough Therapy Designation and Strong Financial Position
- Stoke Therapeutics Advances in RNA Medicine and Financial Growth
- Promising Potential and Strong Financial Position Drive Buy Rating for Stoke Therapeutics